These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38070635)

  • 1. Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients.
    Rehberger Likozar A; Ugovšek S; Šebeštjen M
    Eur J Pharmacol; 2024 Jan; 963():176232. PubMed ID: 38070635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.
    Likozar AR; Šebeštjen M
    Cardiovasc Ultrasound; 2023 Aug; 21(1):15. PubMed ID: 37580777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
    J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
    Stiekema LCA; Stroes ESG; Verweij SL; Kassahun H; Chen L; Wasserman SM; Sabatine MS; Mani V; Fayad ZA
    Eur Heart J; 2019 Sep; 40(33):2775-2781. PubMed ID: 30561610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
    Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis.
    Nagendra L; Mahajan K; Gupta G; Dutta D
    Indian Heart J; 2023; 75(6):416-422. PubMed ID: 37777180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
    J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies.
    Mahmood T; Minnier J; Ito MK; Li QH; Koren A; Kam IW; Fazio S; Shapiro MD
    Eur J Prev Cardiol; 2021 Jul; 28(8):816-822. PubMed ID: 34298554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Different Types and Dosages of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) Levels: A Network Meta-analysis.
    Yu Z; Hu L; Sun C; Wang Z; Zhang X; Wu M; Liu L
    J Cardiovasc Pharmacol; 2023 Jun; 81(6):445-453. PubMed ID: 36972559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
    Julius U; Tselmin S; Schatz U; Fischer S; Bornstein SR
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):45-50. PubMed ID: 30838555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
    O'Donoghue ML; Fazio S; Giugliano RP; Stroes ESG; Kanevsky E; Gouni-Berthold I; Im K; Lira Pineda A; Wasserman SM; Češka R; Ezhov MV; Jukema JW; Jensen HK; Tokgözoğlu SL; Mach F; Huber K; Sever PS; Keech AC; Pedersen TR; Sabatine MS
    Circulation; 2019 Mar; 139(12):1483-1492. PubMed ID: 30586750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.
    Shapiro MD; Minnier J; Tavori H; Kassahun H; Flower A; Somaratne R; Fazio S
    J Am Heart Assoc; 2019 Feb; 8(4):e010932. PubMed ID: 30755061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic.
    Chakraborty A; Pang J; Chan DC; Barnett W; Woodward AM; Vorster M; Watts GF
    Clin Cardiol; 2021 Jun; 44(6):805-813. PubMed ID: 33955565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.